FENNEC PHARMACEUTICALS INC.
FENC evidence brief
What we can confirm
- BioSniper Score:
- 4.9 / 10
- Market Cap:
- $384.3M
- Lead Asset:
- pedmark (Approved)
What it means
What to watch
Prepared research question
What matters most for FENC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FENC
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on preventing cisplatin-induced ototoxicity with its approved product PEDMARK® (sodium thiosulfate).
Key risk: Single-product dependency
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 catalyst · 1 FDA decision for FENNEC PHARMACEUTICALS INC..
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on preventing cisplatin-induced ototoxicity with its approved product PEDMARK® (sodium thiosulfate).
- Cash and equivalents of $41.2M as of 2026-06-30 [sec].
- Total revenue of $17.9M and net income of $2.0M for the period ending 2026-06-30 [sec].
- PEDMARK® is the only FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors [sec_mda · as of 2026-08-13].
- Q2 2026 net product sales of $17.1M, up 78% year-over-year [news · published 2026-08-11].
- Japan clinical trial (STS-J01) reported positive topline results in December 2025 [sec_mda · as of 2026-08-13].
What works
- PEDMARK® is the only FDA-approved therapy for its indication, providing a clear market position [sec_mda · as of 2026-08-13].
- Revenue growth is strong, with Q2 2026 net product sales up 78% year-over-year [news · published 2026-08-11].
- The company has a partnership with Norgine for commercialization in Europe, with launches in Germany and the U.K. in 2025 [sec_mda · as of 2026-08-13].
- Investigator-initiated trials are expanding the evidence base into adult and AYA populations, potentially broadening the market [sec_mda · as of 2026-08-13].
What to weigh
- The company is heavily reliant on a single product, PEDMARK®, for its revenue [sec_mda · as of 2026-08-13].
- Fennec has not yet received any milestone payments from its Norgine partnership [sec_mda · as of 2026-08-13].
- Working capital requirements are subject to substantial uncertainty, and the company continues to pursue strategic alternatives [sec_mda · as of 2026-08-13].
- PEDMARK® is not currently approved for adult or AYA populations, limiting its current market [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
PEDMARK® is the only FDA-approved therapy for its indication.
“PEDMARK ® is currently the only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.”
SEC MD&A · August 13, 2026
Q2 2026 net product sales were $17.1 million, up 78% year-over-year.
“2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year”
News · August 11, 2026
Japan STS-J01 trial reported positive topline results in December 2025.
“In December 2025, we announced positive topline res”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2039-07-01 · Patent_Expiry · SODIUM THIOSULFATE — Patent_Expiry: NDA212937 — The patent for sodium thiosulfate (PEDMARK®) is set to expire, which could open the door for generic competition.
Risks & what to watch (4)›
Key risks
- Single-product dependency — Revenue is entirely dependent on PEDMARK®; no other approved products [sec_mda · as of 2026-08-13].
- Uncertain working capital needs — Working capital requirements are subject to substantial uncertainty [sec_mda · as of 2026-08-13].
- No milestone payments yet — Fennec has not received any milestone payments from its Norgine partnership [sec_mda · as of 2026-08-13].
- Patent expiry approaching — Patent for sodium thiosulfate (NDA212937) expires on 2039-07-01 [catalyst].
What to watch
- Japan registration plans following positive STS-J01 topline results [sec_mda · as of 2026-08-13].
- Expansion of PEDMARK® into adult and AYA populations through investigator-initiated trials [sec_mda · as of 2026-08-13].
- Norgine's further European launches in 2026 and potential milestone payments [sec_mda · as of 2026-08-13].
- Revenue growth trajectory and cash position updates in upcoming quarterly reports [news · published 2026-08-11].
Sources: News · Pipeline · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run FENNEC PHARMACEUTICALS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FENNEC PHARMACEUTICALS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.78 · 5% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~4642d
0 buys · 6 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
90
Total value held
$99.1M
| Holder | Shares | Value |
|---|---|---|
| rosalind advisors, inc. | 2,908,201 | $17.9M |
| southpoint capital advisors lp | 2,744,741 | $16.9M |
| solas capital management, llc | 2,482,198 | $15.3M |
| aigh capital management llc | 1,981,501 | $12.2M |
| blackrock, inc. | 1,368,176 | $8.4M |
| vanguard capital management llc | 897,144 | $5.5M |
| awm investment company, inc. | 720,135 | $4.4M |
| geode capital management, llc | 371,738 | $2.3M |
| state street corp | 359,055 | $2.2M |
| potomac capital management, inc. | 224,400 | $1.4M |
Showing top 10 of 90 institutional holders of FENNEC PHARMACEUTICALS INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 3.6%
- Days to cover
- 3.7
- Shares short
- 930,606
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FENC short interestGovernance
Frequently asked questions
What is the AI investment thesis for FENNEC PHARMACEUTICALS INC.?
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on preventing cisplatin-induced ototoxicity with its approved product PEDMARK® (sodium thiosulfate).
What is FENNEC PHARMACEUTICALS INC.'s lead drug candidate?
FENNEC PHARMACEUTICALS INC.'s most advanced tracked candidate is pedmark (Approved) for reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.
What is FENNEC PHARMACEUTICALS INC.'s next catalyst?
FENNEC PHARMACEUTICALS INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA212937" — expected July 1, 2039.
Who is the CEO of FENNEC PHARMACEUTICALS INC.?
Mr. Jeffrey S. Hackman is the chief executive officer of FENNEC PHARMACEUTICALS INC. (FENC).
Where is FENNEC PHARMACEUTICALS INC. headquartered?
FENNEC PHARMACEUTICALS INC. (FENC) is headquartered in Research Triangle Park, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.